🔎 Trials Near Me

Home › Alcohol Use Disorder (AUD) › NCT06712602

PT150 Drug for Use in Alcohol Use Disorder

RecruitingPhase 1

Selective Glucocorticoid Receptor Antagonism in Alcohol Use Disorder: A Human Laboratory Study

Who can join

Ages 21 to 55 · All sexes

Full eligibility criteria
Inclusion Criteria:

Meet diagnostic criteria for AUD (moderate or severe) per the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5)

Not seeking treatment at the time of the study

English-speaking

Between the ages of 21 and 55 years (individuals under 21 are excluded based on the recommendations of NIAAA that alcohol should not be administered to individuals under the legal drinking age)

Abstinent from alcohol no more than 3 days per week on average

Physically and psychiatrically healthy other than the diagnoses for AUD or tobacco use disorder

ECG, read by cardiologist, within normal limits

Body mass index of 19 - 35

Using an effective form of birth control (e.g., birth control pills, surgical sterilization, condoms, IUD, cervical cap with a spermicide or abstinence) if female

Able to abstain from ALC for 12 hours prior to sessions

No contraindications to ALC or PT150

Exclusion Criteria:

Meet diagnostic criteria for SUDs, save nicotine, other than AUD that in the opinion of a study physician would require medical intervention (e.g., opioid use disorder) or compromise the well-being of the participant

Have abnormal blood chemistry, complete blood count or urinalysis values deemed clinically significant

Have a history of serious physical disease or current physical disease (e.g., impaired cardiovascular functioning, histories of seizure, head trauma or CNS tumors)

Have a current or past history of psychiatric disorder that would interfere with participation (e.g., psychotic \[schizophrenia, schizoaffective\]), bipolar, major depressive disorder)

Have had suicidal ideations in the past 90 days

Pregnant or nursing

Are unwilling/unable to comply with study procedures

Participants scoring \>6 on the Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-Ar); the CIWA-Ar will be administered prior to each experimental session participants who score \>6 will be excluded further participation.

About the study

The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.

What is being tested

Sponsor: Pop Test Oncology LLC · Participants: 34 · Started: Feb 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06712602

Locations in the U.S.

KentuckyUniversity of Kentucky, Lexington

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.